Loading
T-E Meds is a Taipei company that builds antibody-drug conjugates, antibodies that carry drugs to cancer cells, using linkers that hold several drug molecules at once. Its HER2 medicine TE-1182 carries two different cell-killing drugs and has orphan drug status for gastric cancer.
T-E Meds Inc., in Nangang District, Taipei, was established in 2022 as the second subsidiary of T-E Pharma Holding, according to the company. It uses a multi-arm linker platform to make drug bundles that are site-specifically conjugated to antibodies, producing homogeneous high drug-to-antibody-ratio antibody-drug conjugates and antibody-radionuclide conjugates; it says its candidates, for multiple myeloma, pancreatic cancer and HER2-related cancers, are in preclinical development. Its HER2 candidate TE-1182, made with CHO Pharma, carries both MMAF and exatecan on trastuzumab. On 6 October 2026 the FDA granted orphan drug designation for gastric cancer to a trastuzumab-MMAF/exatecan dual-payload antibody-drug conjugate sponsored by T-E Meds.
TE-1182 is an experimental antibody-drug conjugate from T-E Meds that carries two different cell-killing drugs to cancer cells with HER2 on their surface. It has been tested only in the laboratory, and the FDA has given it orphan drug status for gastric cancer.
Shares Dual-payload ADC, HER2, Antibody-drug conjugate (ADC).
Shares Dual-payload ADC, HER2, Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/